8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Feb 26, 2026·SEC
TG Therapeutics, Inc.(TGTX)Earnings, Financials & Key Ratios
TGTX•NASDAQ
19.2× P/E·Price updated Jun 19, 2026
AboutTG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.Show more
- Revenue$616M+87.3%
- EBITDA$124M+192.8%
- Net Income$447M+1812.4%
- EPS (Diluted)2.77+1746.7%
- Gross Margin83.66%-5.3%
- EBITDA Margin20.05%+56.3%
- Operating Margin20.01%+57.0%
- Net Margin72.56%+920.9%
- ROE102.75%+741.2%
TGTX Key Insights
TG Therapeutics, Inc. (TGTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 42.2%
- ✓Momentum leader: RS Rating 93 (top 7%)
- ✓Strong 5Y sales CAGR of 426.7%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Negative free cash flow
- ✗Expensive at 13.3x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TGTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TGTX Price & Volume
TG Therapeutics, Inc. (TGTX) stock price & volume — 10-year historical chart
Loading chart...
TGTX Growth Metrics
TG Therapeutics, Inc. (TGTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years129.45%
5 Years426.73%
3 Years504.86%
TTM81.26%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM1079.81%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM1070.69%
Return on Capital
10 Years-114.01%
5 Years-27.68%
3 Years12.86%
Last Year17.66%
TGTX Recent Earnings
TG Therapeutics, Inc. (TGTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.17-26.1%
$0.23
Rev
$205M+2.3%
$200M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.14-60.0%
$0.35
Rev
$193M+0.4%
$192M
Q4 2025
Nov 3, 2025Metric
Actual
Est
EPS
$2.43+912.5%
$0.24
Rev
$162M-16.6%
$194M
Q3 2025
Aug 4, 2025Metric
Actual
Est
EPS
$0.17-46.9%
$0.32
Rev
$141M-3.5%
$146M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.17vs $0.23-26.1% | $205Mvs $200M+2.3% |
| Q1 2026 | Feb 26, 2026 | $0.14vs $0.35-60.0% | $193Mvs $192M+0.4% |
| Q4 2025 | Nov 3, 2025 | $2.43vs $0.24+912.5% | $162Mvs $194M-16.6% |
| Q3 2025 | Aug 4, 2025 | $0.17vs $0.32-46.9% | $141Mvs $146M-3.5% |
Based on last 12 quarters of dataView full earnings history →
TGTX Peer Comparison
TG Therapeutics, Inc. (TGTX) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 VRTX | 114.88B | 451.63 | 29.48 | 9.57% | 35.4% | 23.93% | 0.21 | |
 ALKS | 7.5B | 44.99 | 31.46 | -5.25% | 9.78% | 8.82% | 0.04 | |
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 | |
 GILD | 153.66B | 123.76 | 18.25 | 2.39% | 30.99% | 42.33% | 1.09 |
Compare TGTX vs Peers
TG Therapeutics, Inc. (TGTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TGTX Income Statement
TG Therapeutics, Inc. (TGTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 152.38K | 152K | 152K | 152K | 6.69M | 2.79M | 233.66M | 329M | 616.29M | 700.35M |
Revenue Growth % | 0% | -0.25% | 0% | 0% | 4300.66% | -58.36% | 8290.02% | 40.8% | 87.32% | 81.26% |
Cost of Goods Sold | 82.36K | 88K | 0 | 0 | 790K | 265K | 14.13M | 38.49M | 100.71M | 118.75M |
COGS % of Revenue | 54.05% | 57.89% | - | - | 11.81% | 9.52% | 6.05% | 11.7% | 16.34% | - |
Gross Profit | 70.03K▲ 0% | 64K▼ 8.6% | 152K▲ 137.5% | 152K▲ 0.0% | 5.9M▲ 3780.9% | 2.52M▼ 57.3% | 219.53M▲ 8611.5% | 290.52M▲ 32.3% | 515.57M▲ 77.5% | 581.6M▲ 0% |
Gross Margin % | 45.95% | 42.11% | 100% | 100% | 88.19% | 90.48% | 93.95% | 88.3% | 83.66% | 83.04% |
Gross Profit Growth % | -21.69% | -8.61% | 137.5% | 0% | 3780.92% | -57.28% | 8611.55% | 32.34% | 77.47% | - |
Operating Expenses | 118.86M | 174.55M | 169.21M | 273.75M | 350.67M | 220.84M | 198.9M | 248.59M | 392.25M | 432.11M |
OpEx % of Revenue | 78004.56% | 114836.84% | 111320.39% | 180096.05% | 5242.47% | 7929.48% | 85.12% | 75.56% | 63.65% | - |
Selling, General & Admin | 16.33M | 15.16M | 15.03M | 107.85M | 128.09M | 95.48M | 122.71M | 154.3M | 232.03M | 254.78M |
SG&A % of Revenue | 10717.22% | 9974.34% | 9886.18% | 70953.95% | 1914.93% | 3428.51% | 52.51% | 46.9% | 37.65% | - |
Research & Development | 96.89M | 153.79M | 154.18M | 165.9M | 222.58M | 125.35M | 76.19M | 94.29M | 160.22M | 157.37M |
R&D % of Revenue | 63581.51% | 101179.61% | 101434.21% | 109142.11% | 3327.54% | 4500.97% | 32.61% | 28.66% | 26% | - |
Other Operating Expenses | -58.74K | 61K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1000K |
Operating Income | -118.71M▲ 0% | -174.4M▼ 46.9% | -169.06M▲ 3.1% | -273.59M▼ 61.8% | -344.77M▼ 26.0% | -218.32M▲ 36.7% | 20.63M▲ 109.5% | 41.93M▲ 103.2% | 123.32M▲ 194.1% | 149.5M▲ 0% |
Operating Margin % | -77904.56% | -114736.84% | -111220.39% | -179996.05% | -5154.28% | -7838.99% | 8.83% | 12.74% | 20.01% | 21.35% |
Operating Income Growth % | -50.33% | -46.91% | 3.06% | -61.84% | -26.02% | 36.68% | 109.45% | 103.21% | 194.13% | - |
EBITDA | -118.63M | -174.31M | -168.77M | -273.22M | -344.28M | -217.8M | 21.06M | 42.21M | 123.57M | 149.69M |
EBITDA Margin % | -77850.52% | -114678.95% | -111034.87% | -179750% | -5146.9% | -7820.5% | 9.01% | 12.83% | 20.05% | 21.37% |
EBITDA Growth % | -50.34% | -46.94% | 3.18% | -61.89% | -26.01% | 36.74% | 109.67% | 100.46% | 192.75% | 149.16% |
D&A (Non-Cash Add-back) | 82.36K | 88K | 282K | 374K | 494K | 515K | 423K | 280K | 244K | 188K |
EBIT | -117.63M | -172.6M | -167.58M | -273.05M | -342.46M | -213.62M | 25.68M | 49.62M | 134.12M | 156.69M |
Net Interest Income | -845K | -877K | -5.29M | -6.33M | -5.64M | -10.19M | -12.62M | -24.03M | -26.73M | -27.64M |
Interest Income | 294.48K | 857K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 1.14M | 1.73M | 5.29M | 6.33M | 5.64M | 10.19M | 12.62M | 24.03M | 26.73M | 27.64M |
Other Income/Expense | 235.99K | 918K | -3.82M | -5.79M | -3.33M | -5.5M | -7.57M | -16.34M | -15.93M | -27.21M |
Pretax Income | -118.48M▲ 0% | -173.48M▼ 46.4% | -172.87M▲ 0.4% | -279.38M▼ 61.6% | -348.1M▼ 24.6% | -223.81M▲ 35.7% | 13.06M▲ 105.8% | 25.59M▲ 95.9% | 107.39M▲ 319.6% | 122.28M▲ 0% |
Pretax Margin % | -77749.86% | -114132.89% | -113730.92% | -183803.29% | -5204.08% | -8036.34% | 5.59% | 7.78% | 17.43% | 17.46% |
Income Tax | -235.74K | -918K | 0 | 0 | 0 | 0 | 390K | 2.21M | -339.79M | -340.78M |
Effective Tax Rate % | 0.2% | 0.53% | 0% | 0% | 0% | 0% | 2.99% | 8.64% | -316.41% | -278.68% |
Net Income | -118.48M▲ 0% | -173.48M▼ 46.4% | -172.87M▲ 0.4% | -279.38M▼ 61.6% | -348.1M▼ 24.6% | -223.81M▲ 35.7% | 12.67M▲ 105.7% | 23.38M▲ 84.5% | 447.18M▲ 1812.4% | 461.9M▲ 0% |
Net Margin % | -77749.86% | -114132.89% | -113730.92% | -183803.29% | -5204.08% | -8036.34% | 5.42% | 7.11% | 72.56% | 65.95% |
Net Income Growth % | -51.4% | -46.43% | 0.35% | -61.61% | -24.6% | 35.7% | 105.66% | 84.52% | 1812.41% | 1079.81% |
Net Income (Continuing) | -118.48M | -173.48M | -172.87M | -279.38M | -348.1M | -223.81M | 12.67M | 23.38M | 447.18M | 461.9M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.91▲ 0% | -2.30▼ 20.4% | -1.96▲ 14.8% | -2.42▼ 23.5% | -2.63▼ 8.7% | -1.46▲ 44.5% | 0.09▲ 105.8% | 0.15▲ 75.8% | 2.77▲ 1746.7% | 2.89▲ 0% |
EPS Growth % | -19.38% | -20.42% | 14.78% | -23.47% | -8.68% | 44.49% | 105.84% | 75.85% | 1746.67% | 1070.69% |
EPS (Basic) | -1.91 | -2.30 | -1.96 | -2.42 | -2.63 | -1.46 | 0.09 | 0.16 | 3.10 | - |
Diluted Shares Outstanding | 62.07M | 75.47M | 88.37M | 115.33M | 132.22M | 135.41M | 148.51M | 160.34M | 161.41M | 160.06M |
Basic Shares Outstanding | 62.07M | 75.47M | 88.37M | 115.33M | 132.22M | 135.41M | 141.96M | 145.32M | 144.32M | 144.44M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
TGTX Balance Sheet
TG Therapeutics, Inc. (TGTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 93.32M | 79.03M | 149.15M | 611.74M | 330.96M | 168.27M | 317.94M | 566.36M | 630.76M | 1.09B |
Cash & Short-Term Investments | 84.83M | 68.81M | 140.44M | 605.43M | 314.76M | 161.68M | 217.51M | 311M | 141.97M | 514.43M |
Cash Only | 56.72M | 41.96M | 112.64M | 553.44M | 298.89M | 102.3M | 92.93M | 179.89M | 79.15M | 442.21M |
Short-Term Investments | 28M | 26.85M | 27.8M | 51.99M | 15.88M | 59.37M | 124.58M | 131.11M | 62.82M | 72.22M |
Accounts Receivable | 108.47K | 95K | 0 | 0 | 1.39M | 0 | 51.09M | 129.19M | 305.63M | 392.05M |
Days Sales Outstanding | 259.81 | 228.13 | - | - | 75.79 | - | 79.81 | 143.32 | 181.01 | 155.64 |
Inventory | 7.95M | 9.69M | 0 | 0 | 0 | 0 | 39.82M | 110.46M | 125.59M | 129.03M |
Days Inventory Outstanding | 35.22K | 40.2K | - | - | - | - | 1.03K | 1.05K | 455.14 | 427.85 |
Other Current Assets | 328.32K | 344K | 611K | 1.08M | 2.88M | 2.36M | 5.34M | 15.72M | 57.58M | 51.46M |
Total Non-Current Assets | 4.06M | 4.58M | 13.86M | 13.9M | 48.66M | 25.3M | 11.64M | 11.33M | 432.49M | 441.87M |
Property, Plant & Equipment | 2.68M | 2.54M | 11.81M | 11.84M | 11.07M | 10.82M | 8.05M | 7.15M | 6.28M | 6.48M |
Fixed Asset Turnover | 0.06x | 0.06x | 0.01x | 0.01x | 0.60x | 0.26x | 29.03x | 46.01x | 98.17x | 107.84x |
Goodwill | 799.39K | 799K | 799K | 799K | 799K | 799K | 799K | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 587.29K | 1.24M | 0 | 0 | 35.53M | 12.4M | 0 | 808K | 59.14M | 198.02M |
Other Non-Current Assets | 587.29K | 1.24M | 1.25M | 1.26M | 1.26M | 1.27M | 2.79M | 3.37M | 19.07M | 29.71M |
Total Assets | 97.38M▲ 0% | 83.62M▼ 14.1% | 163.01M▲ 95.0% | 625.64M▲ 283.8% | 379.63M▼ 39.3% | 193.57M▼ 49.0% | 329.59M▲ 70.3% | 577.69M▲ 75.3% | 1.06B▲ 84.1% | 1.53B▲ 0% |
Asset Turnover | 0.00x | 0.00x | 0.00x | 0.00x | 0.02x | 0.01x | 0.71x | 0.57x | 0.58x | 0.65x |
Asset Growth % | 77.76% | -14.14% | 94.96% | 283.8% | -39.32% | -49.01% | 70.27% | 75.28% | 84.05% | 366.9% |
Total Current Liabilities | 27.96M | 38.85M | 84.45M | 87.55M | 65.38M | 53.2M | 53.72M | 90.68M | 153.76M | 187.11M |
Accounts Payable | 25.88M | 36.38M | 0 | 0 | 0 | 0 | 0 | 0 | 107.51M | 0 |
Days Payables Outstanding | 114.69K | 150.88K | - | - | - | - | - | - | 389.62 | 168.94 |
Short-Term Debt | 127.61K | 67K | 0 | 22.18M | 975K | 0 | 0 | 0 | 1.04M | 1.82M |
Deferred Revenue (Current) | 152.38K | 152K | 0 | 0 | 0 | 0 | 152K | 11.41M | 21.23M | 88.73M |
Other Current Liabilities | 0 | 0 | 82.83M | 63.71M | 62.97M | 51.62M | 52.12M | 78.11M | 23.97M | 168.1M |
Current Ratio | 3.34x | 2.03x | 1.77x | 6.99x | 5.06x | 3.16x | 5.92x | 6.25x | 4.10x | 5.81x |
Quick Ratio | 3.05x | 1.78x | 1.77x | 6.99x | 5.06x | 3.16x | 5.18x | 5.03x | 3.29x | 5.12x |
Cash Conversion Cycle | -79.21K | -110.46K | - | - | - | - | - | - | 246.53 | 414.56 |
Total Non-Current Liabilities | 2.43M | 20.73M | 39.95M | 18.74M | 77.09M | 81.78M | 115.36M | 264.65M | 261.47M | 758.6M |
Long-Term Debt | 0 | 0 | 28.97M | 7.72M | 66.79M | 71.14M | 100.12M | 244.43M | 252.67M | 6.59M |
Capital Lease Obligations | 0 | 0 | 10.22M | 10.41M | 9.85M | 10.34M | 9.23M | 8.13M | 7.02M | 21.92M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.36M | 19.81M | 0 | 0 | 0 | 0 | 0 | 0 | -7.02M | 752M |
Total Liabilities | 97.38M | 59.58M | 124.4M | 106.29M | 142.48M | 134.99M | 169.09M | 355.33M | 415.23M | 945.71M |
Total Debt | 127.61K | 67K | 40.8M | 41.98M | 79.05M | 83.06M | 110.8M | 253.72M | 260.73M | 8.42M |
Net Debt | -56.59M | -41.89M | -71.83M | -511.46M | -219.84M | -19.24M | 17.86M | 73.83M | 181.58M | -433.79M |
Debt / Equity | 0.00x | 0.00x | 1.06x | 0.08x | 0.33x | 1.42x | 0.69x | 1.14x | 0.40x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | 5.26x | 6.01x | 2.11x | 0.06x |
Net Debt / EBITDA | - | - | - | - | - | - | 0.85x | 1.75x | 1.47x | -2.90x |
Interest Coverage | -103.23x | -99.54x | -31.70x | -43.14x | -60.74x | -20.96x | 2.04x | 2.07x | 5.02x | 5.67x |
Total Equity | 66.99M▲ 0% | 24.04M▼ 64.1% | 38.62M▲ 60.7% | 519.35M▲ 1244.9% | 237.15M▼ 54.3% | 58.59M▼ 75.3% | 160.5M▲ 174.0% | 222.36M▲ 38.5% | 648.02M▲ 191.4% | 583.13M▲ 0% |
Equity Growth % | 86.78% | -64.12% | 60.65% | 1244.94% | -54.34% | -75.3% | 173.95% | 38.54% | 191.42% | 608.85% |
Book Value per Share | 1.08 | 0.32 | 0.44 | 4.50 | 1.79 | 0.43 | 1.08 | 1.39 | 4.01 | 3.64 |
Total Shareholders' Equity | 66.99M | 24.04M | 38.62M | 519.35M | 237.15M | 58.59M | 160.5M | 222.36M | 648.02M | 583.13M |
Common Stock | 73.18K | 84K | 109K | 141K | 143K | 146K | 151K | 156K | 159K | 160K |
Retained Earnings | -354.86M | -528.35M | -701.22M | -980.6M | -1.33B | -1.53B | -1.55B | -1.53B | -1.08B | -1.06B |
Treasury Stock | -234.34K | -234K | -234K | -234K | -234K | -234K | -234K | -8.99M | -100.23M | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TGTX Cash Flow Statement
TG Therapeutics, Inc. (TGTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -93.76M | -128.93M | -132.81M | -214.51M | -295.63M | -176.17M | -31.41M | -40.52M | -24.77M | -13.95M |
Operating CF Margin % | -61532.32% | -84819.08% | -87372.37% | -141123.03% | -4419.7% | -6325.67% | -13.44% | -12.31% | -4.02% | - |
Operating CF Growth % | -52.23% | -37.5% | -3.01% | -61.52% | -37.82% | 40.41% | 82.17% | -28.98% | 38.86% | 158.98% |
Net Income | -118.48M | -173.48M | -172.87M | -279.38M | -348.1M | -198.34M | 12.67M | 23.38M | 447.18M | 461.9M |
Depreciation & Amortization | 82.36K | 88K | 282K | 374K | 494K | 515K | 423K | 280K | 59K | 7.72M |
Stock-Based Compensation | 15.95M | 12.89M | 11.34M | 80.29M | 61.27M | 19.18M | 37.93M | 42.54M | 64.67M | 49.7M |
Deferred Taxes | 61.32K | -119K | -257K | -30K | 517K | 0 | 0 | 0 | -348M | 22.49M |
Other Non-Cash Items | 58.74K | 3.94M | 3.52M | 4M | 2.4M | 4.11M | 2.22M | 2.58M | 5.86M | -340M |
Working Capital Changes | 8.56M | 27.76M | 25.19M | -19.76M | -12.22M | -1.65M | -84.66M | -109.3M | -194.54M | -215.76M |
Change in Receivables | -24.62K | 14K | -11K | -6K | -1.39M | 1.39M | -51.09M | -78.09M | -176.44M | -201.93M |
Change in Inventory | 0 | 0 | 11K | 6K | -15.99M | 0 | -36.94M | -66.85M | -33.45M | -422K |
Change in Payables | 11.02M | 10.96M | -4.79M | 11.63M | 15.99M | -11.01M | 192K | 0 | 55.88M | 24.31M |
Cash from Investing | -8.21M | 1.18M | -718K | -24.51M | -332K | -20.01M | -50.65M | -1.04M | 13.8M | 16.87M |
Capital Expenditures | -2.23K | -90K | -131K | -357K | -401K | -14K | 0 | -45K | -214K | -240K |
CapEx % of Revenue | 1.46% | 59.21% | 86.18% | 234.87% | 5.99% | 0.5% | - | 0.01% | 0.03% | 0.03% |
Acquisitions | 0 | 0 | 587K | 24.15M | -69K | 20M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -8.21M | 1.27M | -587K | -24.15M | 69K | -20M | 0 | 0 | 0 | 14.2M |
Cash from Financing | 133.66M | 113.64M | 204.21M | 679.83M | 41.42M | -391K | 72.7M | 128.53M | -89.73M | 307.2M |
Debt Issued (Net) | 0 | 0 | 29.99M | 0 | 40M | -975K | 25M | 137.26M | 0 | 490.06M |
Equity Issued (Net) | 133.66M | 113.64M | 175.02M | 679.68M | 2.22M | 584K | 46.3M | -8.76M | -89.73M | -183.29M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -8.76M | -91.24M | -185.11M |
Other Financing | 0 | 0 | -795K | 147K | -800K | 0 | 1.41M | 25K | 0 | 432K |
Net Change in Cash | 31.69M▲ 0% | -14.11M▼ 144.5% | 70.69M▲ 601.1% | 440.81M▲ 523.6% | -254.55M▼ 157.7% | -196.57M▲ 22.8% | -9.36M▲ 95.2% | 86.97M▲ 1029.3% | -100.7M▼ 215.8% | 310.11M▲ 0% |
Free Cash Flow | -93.77M▲ 0% | -129.01M▼ 37.6% | -132.94M▼ 3.0% | -214.86M▼ 61.6% | -296.04M▼ 37.8% | -176.18M▲ 40.5% | -31.41M▲ 82.2% | -40.56M▼ 29.1% | -24.99M▲ 38.4% | -14.19M▲ 0% |
FCF Margin % | -61533.78% | -84878.29% | -87458.55% | -141357.89% | -4425.7% | -6326.18% | -13.44% | -12.33% | -4.05% | -2.03% |
FCF Growth % | -51.39% | -37.59% | -3.04% | -61.63% | -37.78% | 40.49% | 82.17% | -29.12% | 38.4% | 76.77% |
FCF per Share | -1.51 | -1.71 | -1.50 | -1.86 | -2.24 | -1.30 | -0.21 | -0.25 | -0.15 | -0.09 |
FCF Conversion (FCF/Net Income) | 0.79x | 0.74x | 0.77x | 0.77x | 0.85x | 0.79x | -2.48x | -1.73x | -0.06x | -0.03x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18.47M | 0 | 12.2M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 500K | 0 | 1.96M |
TGTX Key Ratios
TG Therapeutics, Inc. (TGTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -230.36% | -381.16% | -551.85% | -100.14% | -92.03% | -151.36% | 11.57% | 12.21% | 102.75% | 87.36% |
Return on Invested Capital (ROIC) | -835.68% | - | - | - | -2052.2% | -578% | 14.22% | 13.25% | 16.43% | 20.7% |
Gross Margin | 45.95% | 42.11% | 100% | 100% | 88.19% | 90.48% | 93.95% | 88.3% | 83.66% | 83.04% |
Net Margin | -77749.86% | -114132.89% | -113730.92% | -183803.29% | -5204.08% | -8036.34% | 5.42% | 7.11% | 72.56% | 65.95% |
Debt / Equity | 0.00x | 0.00x | 1.06x | 0.08x | 0.33x | 1.42x | 0.69x | 1.14x | 0.40x | 0.01x |
Interest Coverage | -103.23x | -99.54x | -31.70x | -43.14x | -60.74x | -20.96x | 2.04x | 2.07x | 5.02x | 5.67x |
FCF Conversion | 0.79x | 0.74x | 0.77x | 0.77x | 0.85x | 0.79x | -2.48x | -1.73x | -0.06x | -0.03x |
Revenue Growth | 0% | -0.25% | 0% | 0% | 4300.66% | -58.36% | 8290.02% | 40.8% | 87.32% | 81.26% |
Related:TGTX Dividend History·TGTX Revenue History·TGTX Price History·TGTX P/E History·TGTX Financial Ratios·TGTX Institutional Holders
TGTX SEC Filings & Documents
TG Therapeutics, Inc. (TGTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
TGTX Frequently Asked Questions
TG Therapeutics, Inc. (TGTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
TG Therapeutics, Inc. (TGTX) reported $700.3M in revenue for fiscal year 2025. This represents a 700249% increase from $0.1M in 1996.
TG Therapeutics, Inc. (TGTX) grew revenue by 87.3% over the past year. This is strong growth.
Yes, TG Therapeutics, Inc. (TGTX) is profitable, generating $461.9M in net income for fiscal year 2025 (72.6% net margin).
Dividend & Returns
TG Therapeutics, Inc. (TGTX) has a return on equity (ROE) of 102.8%. This is excellent, indicating efficient use of shareholder capital.
TG Therapeutics, Inc. (TGTX) had negative free cash flow of $14.2M in fiscal year 2025, likely due to heavy capital investments.